Back to search

Article

Severe anemia as a risk factor in Japanese patients with ovarian cancer receiving olaparib: A retrospective study

2026-03-03

Abstract excerpt

<title>Abstract</title> <p> Background: Ovarian cancer is often diagnosed at an advanced stage, and recurrence after initial platinum-based chemotherapy remains a major challenge. Olaparib, a poly (ADP-ribose) polymerase inhibitor, is an essential maintenance therapy, particularly for patients with homologous recombination deficiency, with proven efficacy. However, hematologic toxicity—especially anemia—is comm...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
5fdc14f4-bade-5a4e-860f-eb533a5ef5e4
DOI
10.21203/rs.3.rs-8806671/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Severe anemia as a risk factor in Japanese patients with ovarian cancer receiving olaparib: A retrospective studyDOI 10.21203/rs.3.rs-8806671/v1
Real-world data of poly (ADP-ribose) polymerase inhibitor response in Japanese patients with ovarian cancer.Semantic proximity
Managing Adverse Effects Associated With Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer: A Synthesis of Clinical Trial and Real-World DataSemantic proximity
Real-world efficacy and toxicity of olaparib maintenance therapy in Korean ovarian cancer patients with an exploratory analysis of BRCA mutations.Semantic proximity
Maintenance olaparib monotherapy in patients with platinum-sensitive relapsed ovarian cancer without a germline BRCA1 and/or BRCA2 mutation: Final overall survival results from the OPINION trialSemantic proximity
Overall Survival and the Evolving Benefit-Risk Assessment for Poly (ADP-ribose) Polymerase Inhibitors in Advanced Ovarian CancerSemantic proximity
Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial.Semantic proximity
Health-Related Quality of Life in PARP-Inhibitor Olaparib Maintenance in Ovarian Cancer Patients: Real World Data and Experience of a Single-Center in ChinaSemantic proximity
Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis.Semantic proximity
First evidence of olaparib maintenance therapy in patients with newly diagnosed homologous recombination deficient positive/BRCA wild-type ovarian cancer: real-world multicenter studySemantic proximity
Adverse event profile following maintenance olaparib in patients with BRCA-mutated platinum-sensitive relapsed serous ovarian cancer in the phase III SOLO2 trial.Semantic proximity
HSP90 is a potential risk factor for ovarian cancer prognosis: an evidence of a Chinese clinical centerSemantic proximity
Niraparib-Related Pulmonary Embolism During Ovarian Cancer TherapySemantic proximity
Select a neighboring publication to make it the new centre.